| SHCBP1 | SHC SH2-domain binding protein 1 |
| mPAL | Murine protein of activated lymphocytes |
| NSCLC | Non-small cell lung carcinoma |
| HCC | Hepatocellular carcinoma |
| CDK | Cyclin-dependent kinase |
| EMT | Epithelial–mesenchymal transition |
| PbH1 | Parallel beta-helix |
| PLK1 | Polo-like kinase 1 |
| EGF | Epidermal growth factor |
| TGF-β | Transforming growth factor β |
| MiRNA | MicroRNA |
| LncRNA | Long noncoding RNA |
| CeRNA | Competing endogenous RNA |
| AURKB | Aurora kinase B |
| FGF | Fibroblast growth factor |
| USP49 | Ubiquitin-specific peptidase 49 |
| CBP | CREB binding protein |
| HNSCC | Head and neck squamous cell carcinoma |
| VEGF | Vascular endothelial growth factor |
| RTK | Receptor tyrosine kinase |
| PDAC | Pancreatic ductal adenocarcinoma |
| EOGT | EGF domain specific O-linked GlcNActransferase |
| TME | Tumor microenvironment |
| TAM | Tumor-associated macrophage |
| TMB | Tumor mutation burden |
| MSI | Microsatellite instability |
| CAG | Cancer–associated fibroblast |
| ICI | Immune checkpoint inhibitor |
| PPI | Protein–protein interaction |
| SCLC | Small cell lung cancer |
| RNAi | RNA interference |
| SiRNA | Small interfering RNA |
| ShRNA | Short hairpin RNA |
| TFBG | Theaflavin-3,3′-digallate |